RT Journal Article
SR Electronic
T1 Use of the Vitiligo Extent Score Vitiligo: A Protocol for a Scoping Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.16.22282239
DO 10.1101/2022.11.16.22282239
A1 Rueda-Galvis, Paola Andrea
A1 Orozco-Jiménez, Sara
A1 Builes-Montaño, Carlos E.
A1 Arango-Salgado, Andrea
YR 2022
UL http://medrxiv.org/content/early/2022/12/20/2022.11.16.22282239.abstract
AB Introduction Vitiligo is a chronic skin condition with no cure. Clinical assessment and treatment evaluation relays heavily on clinometry tools and expert knowledge. The Vitiligo Extent Score has been proposed as one of the most reliable and easy-to-use clinometry tools for vitiligo.Methods and analysis We proposed a scoping review to identify all the available evidence on the clinical research availability around the Vitiligo Extent Score. This review will follow the approach proposed in the Joanna Briggs Institute Reviewer’s Manual Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.Ethics and dissemination We intend to publish the results in a specialized peer-reviewed journal and local, national, and international conference presentations. It will also be incorporated as educational material in our institution’s postgraduate program in dermatology.Strengths and limitations of this study This scoping review will be the first to review the available literature on VES extensively.The search strategy includes an extensive search of grey literature besides the primary medical databases and no language restriction, ensuring the inclusion of all the available literature.The research questions will allow us to assess the main aspects of a measurement instrument.This scoping review will only evaluate one of the several available measurement instruments for vitiligo.Competing Interest StatementThe authors certify that they have no affiliation nor are they involved with any organization or entity with any financial interest (such as fees, financial aid for education, shares, employment contracts, work as consultants or any other type of interest) or non-financial interest (such as personal, professional relationships, affiliations, or beliefs) in the topic of interest or any material discussed in this manuscript. Carlos E. Builes-Montano has received consulting or speaker fees from Sanofi, Novo Nordisk, Novartis, and Boehringer Ingelheim.Funding StatementThe authors received no financial support for the research, authorship, or publication involved in writing this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data was collected in the development of this protocol.